Drug Profile


Alternative Names: APC 8024; BA 7072; Cancer vaccine HER-2/neu - Dendreon; DN24-02; HER-2/neu cancer vaccine - Dendreon; Neuvenge™

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines; Dendritic cell vaccines; T lymphocyte cell therapies
  • Mechanism of Action Antigen-presenting-cell-modulators; ERBB 2 receptor antagonists; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Urogenital cancer
  • Phase I Breast cancer; Colorectal cancer; Ovarian cancer

Most Recent Events

  • 27 Aug 2015 Phase-II development for Urogenital cancer is ongoing in USA
  • 01 Jul 2015 Dendreon completes the phase II NeuACT trial in Urothelial carcinoma (Adjuvant therapy, HER2-positive) in USA (NCT01353222)
  • 23 Feb 2015 Valeant Pharmaceuticals International acquires Dendreon Corporation's assets, presumably including lapuleucel-T
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top